Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 3/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL415891 | 0.84 | RAB9A (0.44) | NPC1RAB9AMEN1KMT2ABRAF | |
| SCHEMBL416571 | 0.81 | DPP4 (0.38) | RPA1NPC1RAB9AHRH4 | |
| SCHEMBL418233 | 0.79 | HSP90AA1 (0.40) | RPA1RAB9ABRAF | |
| SCHEMBL419511 | 0.79 | RPA1 (0.35) | RPA1NPC1RAB9ABRAF | |
| SCHEMBL417818 | 0.78 | RPA1 (0.53) | RPA1NPC1RAB9A | |
| SCHEMBL417954 | 0.71 | ALOX5 (0.40) | RPA1NPC1RAB9A | |
| SCHEMBL419740 | 0.70 | PGR (0.34) | RPA1BRAF | |
| SCHEMBL421270 | 0.69 | PDE4B (0.40) | RAB9AMEN1KMT2ABRAF | |
| SCHEMBL2486902 | 0.69 | RPA1 (0.41) | RPA1CHRM3CHRM2CHRM1 | |
| SCHEMBL421837 | 0.68 | PGR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376479-B1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO KG (DE) | 2016-03-02 | — | — | EP | disclosed |
| US-8324268-B2 | Substituted furancarboxamides, and use thereof | AICURIS GMBH & CO. KG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-8324268-B2 | Substituted furancarboxamides, and use thereof | AICURIS GMBH & CO. KG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-8324268-B2 | Substituted furancarboxamides, and use thereof | AICURIS GMBH & CO. KG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| WO-2010075957-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AADAC, DDC, TPMT | RPA1 4663/4885NPC1 2894/4885RAB9A 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.